Tag Archives: Athersys

Athersys: Remarkable Treatment For Ischemic Stroke Feasibly On The Way

By U.S. Biotech Investor: Introduction Athersys, Inc. (ATHX) is currently engaged in a phase II, double blind, placebo-controlled study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who’ve suffered a moderate … Continue reading

Posted in Finance | Tagged , , , , , | Leave a comment

Athersys, Inc: The Facts

ByBioStocksElite: On March 27, 2013, Seeking Alpha published my article Athersys, Inc. Has Blockbuster Potential. Following that publication I received many requests from investors regarding potential valuation for Athersys (ATHX) so I wrote follow up article Athersys: Valuation that was … Continue reading

Posted in Finance | Tagged , | Leave a comment

Athersys: Valuation

ByBioStocksElite: By: @BioInvestor71 of BioStocksElite.com After the March 27, 2013 article “Athersys, Inc. Has Blockbuster Potential”, I received many requests for further analysis into revenue potential and what would constitute fair present day valuation for Athersys, Inc. (ATHX). Athersys, Inc. … Continue reading

Posted in Finance | Tagged , | Leave a comment

A Candid Conversation With Athersys CEO Gil Van Bokkelen

ByBlackbirdAnalytics: As a follow up to my latest article on Athersys (ATHX), “A Significantly Undervalued Stem Cell Company Approaching Key Catalysts,” here is a candid interview between Blackbird Analytics Founder (Sam) and Athersys CEO Gil Van Bokkelen. This interview goes … Continue reading

Posted in Finance | Tagged , , , | Leave a comment

Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts

ByBlackbirdAnalytics: I suggest investors take a look at an under-followed company called Athersys (ATHX). After decades of debate on the ethics of stem cell research, the rhetoric has ebbed and focus has shifted from ethics to the promises of clinical … Continue reading

Posted in Finance | Tagged , , , , , , , | Leave a comment